WO2005094797A3 - Nouveaux antagonistes de recepteur ampa - Google Patents

Nouveaux antagonistes de recepteur ampa Download PDF

Info

Publication number
WO2005094797A3
WO2005094797A3 PCT/EP2005/002305 EP2005002305W WO2005094797A3 WO 2005094797 A3 WO2005094797 A3 WO 2005094797A3 EP 2005002305 W EP2005002305 W EP 2005002305W WO 2005094797 A3 WO2005094797 A3 WO 2005094797A3
Authority
WO
WIPO (PCT)
Prior art keywords
ampa
receptor antagonists
treating dementia
dementia
nootropics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/002305
Other languages
English (en)
Other versions
WO2005094797A2 (fr
Inventor
Kurt Lingenhoehl
Ferenc Martenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2005094797A2 publication Critical patent/WO2005094797A2/fr
Publication of WO2005094797A3 publication Critical patent/WO2005094797A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé destiné au traitement et/ou à la prévention de la démence qui comprend les étapes consistant à administrer à un animal à sang chaud, notamment un être humain, le nécessitant une quantité efficace d'un antagoniste récepteur AMPA seul ou en combinaison avec des nootropes.
PCT/EP2005/002305 2004-03-05 2005-03-04 Nouveaux antagonistes de recepteur ampa Ceased WO2005094797A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405034.0A GB0405034D0 (en) 2004-03-05 2004-03-05 Organic compounds
GB0405034.0 2004-03-05

Publications (2)

Publication Number Publication Date
WO2005094797A2 WO2005094797A2 (fr) 2005-10-13
WO2005094797A3 true WO2005094797A3 (fr) 2005-12-01

Family

ID=32088811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002305 Ceased WO2005094797A2 (fr) 2004-03-05 2005-03-04 Nouveaux antagonistes de recepteur ampa

Country Status (2)

Country Link
GB (1) GB0405034D0 (fr)
WO (1) WO2005094797A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250281474A1 (en) * 2021-09-15 2025-09-11 University Of The Ryukyus Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0784054A1 (fr) * 1994-09-27 1997-07-16 Yamanouchi Pharmaceutical Co. Ltd. Derive de 1,2,3,4-tetrahydroquinoxalindione
US5756495A (en) * 1994-08-01 1998-05-26 Schering Aktiengesellschaft 3-substituted 3H-2, 3-benzodiazepine derivatives, the production and use as pharmaceutical agents
EP0884316A1 (fr) * 1997-06-09 1998-12-16 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA
WO2000027851A1 (fr) * 1998-11-09 2000-05-18 Gyógyszerkutató Intézet Kft. Nouveaux types de composes de pyridazinone condenses
US6117873A (en) * 1996-10-24 2000-09-12 Novartis Ag Substituted aminoalkane phosphonic acids
WO2003020289A1 (fr) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Traitement de la demence et des troubles de la memoire par le biais d'anticonvulsifs et d'inhibiteurs de l'acetylcholinesterase
WO2003092701A2 (fr) * 2002-04-30 2003-11-13 Novartis Ag Utilisation d'acides amino-alcane-phosphoniques substitués

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756495A (en) * 1994-08-01 1998-05-26 Schering Aktiengesellschaft 3-substituted 3H-2, 3-benzodiazepine derivatives, the production and use as pharmaceutical agents
EP0784054A1 (fr) * 1994-09-27 1997-07-16 Yamanouchi Pharmaceutical Co. Ltd. Derive de 1,2,3,4-tetrahydroquinoxalindione
US6117873A (en) * 1996-10-24 2000-09-12 Novartis Ag Substituted aminoalkane phosphonic acids
EP0884316A1 (fr) * 1997-06-09 1998-12-16 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA
WO2000027851A1 (fr) * 1998-11-09 2000-05-18 Gyógyszerkutató Intézet Kft. Nouveaux types de composes de pyridazinone condenses
WO2003020289A1 (fr) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Traitement de la demence et des troubles de la memoire par le biais d'anticonvulsifs et d'inhibiteurs de l'acetylcholinesterase
WO2003092701A2 (fr) * 2002-04-30 2003-11-13 Novartis Ag Utilisation d'acides amino-alcane-phosphoniques substitués

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CACABELOS R ET AL: "THE GLUTAMATERGIC SYSTEM AND NEURODEGENERATION IN DEMENTIA: PREVENTIVE STRATEGIES IN ALZHEIMER'S DISEASE", INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, JOHN WILEY AND SONS, CHICHESTER, GB, vol. 14, no. 1, 1999, pages 3 - 47, XP000924811, ISSN: 0885-6230 *
KHAN S A ET AL: "TOPIRAMATE ATTENUATES EXAGGERATED ACOUSTIC STARTLE IN AN ANIMAL MODEL OF PTSD", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 2003, 8 November 2003 (2003-11-08), pages ABSTRNO41605, XP008048316, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
WO2005094797A2 (fr) 2005-10-13
GB0405034D0 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
WO2005102338A8 (fr) Methode de traitement de la douleur neuropathique au moyen d'un antagoniste du recepteur crth2
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
WO2005037259A3 (fr) Procedes et compositions de prevention ou de traitement de neoplasie comprenant un inhibiteur de la cox-2 en combinaison avec un antagoniste recepteur du facteur de croissance epidermale
EP1742641A4 (fr) Procedes et compositions de detection et de traitement de maladies de la retine
SI1761266T1 (sl) Spojine, formulacije in postopki za zdravljenje ali preprečevanje vnetnih kožnih motenj
WO2004024150A3 (fr) Methodes de traitement de troubles associes aux recepteurs mglu (metabotropiques du glutamate), notamment la dependance et la depression
WO2005072308A3 (fr) Antagonistes des recepteurs du cgrp
WO2005000194A3 (fr) Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
TW200621306A (en) Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
WO2007141284A3 (fr) Antagonistes du peptide cgrp
WO2006018024A3 (fr) Compositions cosmetiques et pharmaceutiques contenant des inhibiteurs de l'eca et/ou des antagonistes des recepteurs de l'angiotensine ii
WO2006002437A3 (fr) Traitement d'etats pathologiques impliquant la demyelinisation
WO2005016883A3 (fr) Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
WO2005092009A3 (fr) Inhibiteurs d'acetylcholinesterase et antagonistes de n-methyle-d-aspartate utiles dans le traitement de troubles cognitifs
WO2006074265A3 (fr) Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires
WO2006017673A3 (fr) Influence du taj sur les fonctions neuronales
WO2006012641A3 (fr) Procedes de detection et de traitement de troubles auto-immuns
PL1608685T3 (pl) Antagoniści VEGF do leczenia cukrzycy
WO2007100430A3 (fr) Analogues de cystisine et d'acétylcholine et procédés de traitement des troubles de l'humeur
WO2006017822A3 (fr) Derives de quinazoline, utilisation de ces derniers dans le traitement de la thrombocythemie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase